Patents Examined by Barbara S. Frazier
  • Patent number: 10894026
    Abstract: The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 19, 2021
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthymios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Morfis Abatzis, Manolis Fousteris
  • Patent number: 10881609
    Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 5, 2021
    Assignee: Retina Foundation Of The Southwest
    Inventor: Karl Csaky
  • Patent number: 10874689
    Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 29, 2020
    Assignee: Galleon Labs LLC
    Inventor: Gary S. Hahn
  • Patent number: 10864216
    Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: December 15, 2020
    Assignee: WisTa Laboratories, Ltd.
    Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
  • Patent number: 10857086
    Abstract: Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; a cyclic compound selected from the group consisting of a vitamin B3 compound, a xanthine compound, a salicylic acid ester, and mixtures thereof; a compound having at least three large head groups; and an aqueous carrier. The composition of the present invention provides improved hair manageability.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 8, 2020
    Assignee: The Procter and Gamble Company
    Inventor: Mui Siang Soh
  • Patent number: 10842727
    Abstract: Provided is a functional cosmetic composition of white rose extract and a gartanin derivative compound isolated therefrom, and specifically, to a cosmetic composition for skin whitening and skin wrinkle alleviation containing, as active ingredients, white rose petal extract and gartanin derivative compounds isolated therefrom. The white rose extract and gartanin derivative compound, according to the present invention, are safe without causing side effects on the skin, prevent melanin production through a mechanism inhibiting tyrosinase activity, thereby having a whitening effect, and exhibit a wrinkle alleviation effect by a mechanism inhibiting MMP-1 activity, and thus the composition, of the present invention, containing the same as active ingredients, can be utilized as a material for functional cosmetics for skin whitening and wrinkle alleviation without causing skin irritation.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 24, 2020
    Assignees: GANGNEUNG-WONGJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yun-Bae Kim, Seong-Soo Joo
  • Patent number: 10842813
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 24, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Patent number: 10835555
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 17, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Patent number: 10821132
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 3, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Patent number: 10806783
    Abstract: The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R1 represents C1-6alkyl; R2 represents hydrogen or C1-6alkyl; and R3 represents C1-6alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: October 20, 2020
    Assignee: Stabilitech Biopharma Ltd
    Inventor: Jeffrey Drew
  • Patent number: 10786477
    Abstract: Novel active compositions having antimicrobial and anti-inflammatory activity are described, the activity provided by an active component prepared in a suspension, the active component being at least a single chain fatty acid having a carbon length of 12, or between 12 and no more than 18. The fatty acid may be esterified and/or ethylated or methylated. As an antimicrobial the active component has activity against one or more microorganisms including Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp., and Candida spp., with an MIC as low as 0.0018 ?g/ml. As an anti-inflammatory, it is at least as or is more effective than cyclosporine in preventing T-cell proliferation in response to a trigger, such as stimulation by the one or more microorganisms. The active component is more active when combined with a phospholipid (e.g., lecithin, phosphatidylcholine) and caused to form liposomal nanoparticles. It is also more active when caused to form coated liposomal nanoparticles.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: September 29, 2020
    Assignee: Natureza, Inc.
    Inventors: Lynn S. James-Meyer, Gerald C. Coles
  • Patent number: 10765751
    Abstract: A method for treating tumor or inflammation in a patient in need thereof by administering a pH sensitive drug which includes a pH sensitive carrier including at least one amphipathic substance, and a physiologically active substance supported in the pH sensitive carrier to induce the pH sensitive carrier to develop a membrane disruptive function and to deliver the physiologically active substance to the site.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 8, 2020
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventor: Naoki Sakaguchi
  • Patent number: 10758484
    Abstract: The present invention discloses a method for administering SN-38-loaded polymeric micelles into the central nervous system of a human subject via a convection-enhanced delivery system. The convection-enhanced delivery is achieved by using an osmotic pump or an infusion pump. Further, SN-38-loaded polymeric micelles are administered into a target region of the brain of the subject.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 1, 2020
    Assignee: Nippon Kayaku Co., Ltd.
    Inventors: Ryuta Saito, Teiji Tominaga
  • Patent number: 10736821
    Abstract: Silver sulfadiazine-immobilized inorganic fillers are described, and their synthesis is presented. The fillers are believed to have utility in dental composites and dental adhesives to achieve potent, long-term, and none-leaching antimicrobial effects.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: August 11, 2020
    Assignee: University of Massachusetts
    Inventors: Rohit Srivastava, Yuyu Sun
  • Patent number: 10702454
    Abstract: The present invention relates to a solid cosmetic composition in the form of a preferably pressed powder, comprising, in a physiologically acceptable medium, at least: —an oily phase greater than or equal to 20% by weight relative to the total weight of the composition, —a pulverulent phase greater than or equal to 40% by weight relative to the total weight of the composition, comprising at least one spherical filler and at least one lamellar filler, the spherical filler(s) and the lamellar filler(s) being present in a respective total weight content such that the weight ratio of the spherical filler(s) to the lamellar filler(s) is greater than or equal to 0.01 and preferably between 0.02 and 15. The present invention also relates to a product obtained by means of a particular process, to a process for manufacturing a cosmetic composition, and to a process for coating the face with said cosmetic composition.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: July 7, 2020
    Assignee: L'OREAL
    Inventors: Padraig MacDermott, Catherine Sautel, Gwenola Le Gars
  • Patent number: 10682533
    Abstract: A capsule delivery system. The system has a first capsule containing a first capsule wall encapsulating a first active material and a second capsule containing a second capsule wall encapsulating a second active material. The first and second capsules differ in their wall materials, amounts of wall materials, ratios of wall materials, core modifiers, scavengers, active materials, curing temperatures, heating rates, curing times, or a combination thereof. Also provided is a consumer product containing this capsule delivery system.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 16, 2020
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Henricus Gerardus Maria Reijmer, Stephanus Cornelis Maria Otte, Volkert Willem Alexander de Villeneuve, Elizabeth Geertruida Maria Brundel
  • Patent number: 10675323
    Abstract: A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and/or biophysical properties.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: June 9, 2020
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Michelle Hines, Javier Aravena, Brian Jones
  • Patent number: 10668038
    Abstract: Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 2, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Omar Abdelfattah Abu-Baker, Donald MacKenzie, Rennan Pan
  • Patent number: 10668124
    Abstract: A method of reducing inflammation in skin is disclosed. The method can include topically applying to skin in need thereof a composition comprising 0.001 wt. % to 5 wt. % of a kakadu plum fruit extract to reduce TNF-? production in human epidermal keratinocytes of the skin, and 0.001 wt. % to 5 wt. % of an acai berry fruit extract to reduce TNF-? production in human epidermal keratinocytes of the skin, wherein topical application of the composition reduces inflammation in the skin.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 2, 2020
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Michelle Hines, Javier Aravena, Brian Jones
  • Patent number: 10653700
    Abstract: The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: May 19, 2020
    Inventor: John Hsu